Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding

PLoS ONE

Volumn 4, Issue 4, 2009, Pages

  Chamberlain, Janet ^a   Francis, Shiela ^a   Brookes, Zoe ^a   Shaw, Gary ^a   Graham, Delyth ^b   Alp, Nicholas J ^c   Dower, Steven ^a   Crossman, David C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; APOLIPOPROTEIN E; INTERLEUKIN 1 RECEPTOR; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTERITIS; ARTICLE; ATHEROGENESIS; ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; LIPID DIET; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; VASODILATATION; ANIMAL; BLOOD PRESSURE; FAT INTAKE; GENETICS; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION;

MUS;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PRESSURE; DIETARY FATS; INTERLEUKIN-1; MICE; MICE, KNOCKOUT; POLYMERASE CHAIN REACTION; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; RECEPTORS, INTERLEUKIN-1;

EID: 64549109737     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005073     Document Type: Article

References (40)

1. Appel LJ, Sacks FM, Carey VJ, Obarzanek E, Swain JF, et al. (2005) Effects of protein, monosaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA 294: 2455-2464.
2. Hansson GK (2005) Inflammation, Atherosclerosis and Coronary artery Disease. N Engl J Med 352: 1685-1695.
3. Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, et al. (2006) Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 24: 215-233.
4. Glass CK, Witztum JL (2001) Atherosclerosis: The Road Ahead. Cell 104: 503-516.
5. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA (1984) Interleukin-1 induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 160: 618-623.
6. Libby P, Ordovas JM, Birinyi LK, Auger KR, Dinarello CA (1986) Inducible interleukin-1 gene expression in human vascular smooth muscle cells. J Clin Invest 78: 1432-1438.
7. Colotta F, Dower SK, Sims JE, Mantovani A (1994) The Type II 'decoy' receptor ; a novel regulatory pathway for IL-1. Immunol Today 15: 562-526.
8. Symons JA, Young PR, Duff GW (1995) Soluble type II IL-1 receptor binds and blocks processing of IL-1beta precursor and loses affinity for IL-1ra. Proc Natl Acad Sci USA 92: 1714-1718.
9. Tamaru M, Tomura K, Sakamoto S, Tezuka K, Tamatani T, et al. (1998) Interleukin-1 beta induces tissue- and cell-specific expression of adhesion molecules in vivo. Arterioscler Thromb Vasc Biol 18: 1292-1303.
10. Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, et al. (1996) IL-1beta in the coronary arteries of patients with ischaemic heart disease. Arterioscler Thromb Vasc Biol 16: 1000-1006.
11. Dewberry R, Holden H, Crossman D, Francis S (2000) Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol 20: 2394-2400.
12. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, et al. (2003) Lack of interleukin-1β decreases the severity of atherosclerosis in Apo-E deficient mice. Arterioscler Thromb Vasc Biol 23: 656-660.
13. Elhage R, Maret A, Pieraggi MT, Thiers JC, Arnal JF, et al. (1998) Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation 97: 242-244.
14. Isoda K, Sawada S, Ishigami N, Matsuki T, Miyazaki K, et al. (2004) Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 24: 1068-1073.
15. Devlin CM, Kuriakose G, Hirsch E, Tabas I (2002) Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc Natl Acad Sci USA 99: 6280-6285.
16. Chi H, Messas E, Levine RA, Graves DT, Amar S (2004) IL-1 Receptor signaling mediates atherosclerosis associated with bacterial exposure and/or high fat diet in a murine apolipoprotein E Heterozygote model. Circulation 110: 1678-1685.
17. Morton AC, Arnold ND, Gunn J, Varcoe R, Francis SE, et al. (2005) Interleukin-1 receptor antagonist alters the response to vessel wall injury in a porcine coronary artery model. Cardiovasc Res 68: 493-501.
18. Chamberlain J, Evans D, Dower S, Crossman D, Francis S (2006) IL-1β and signaling of IL-1 in vascular wall and circulating cells modulates the extent of neointima formation after vascular injury in mice. Am J Pathol 168: 1396-1403.
19. Brookes ZL, Kaufman S (2003) Myogenic responses and compliance of mesenteric and splenic vasculature in the rat. Am J Physiol Regul Integr Comp Physiol 284: R1604-R1610.
20. Andrew PS, Kaufman S (2003) Guanylyl cyclase mediates ANP-induced vasoconstriction of murine splenic vessels. Am J Physiol Regul Integr Comp Physiol 284: R1567-R1571.
21. Alp NJ, McAteer MA, Khoo J, Choudhury RP, Channon KM (2004) Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. Arterioscler Thromb Vasc Biol 24: 445-450.
22. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, et al. (2001) Endothelial regulation of vasomotion in ApoE-deficient mice. Implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 103: 1282-1288.
23. Alp NJ, Mussa S, Khoo J, Cai S, Guzik T, et al. (2003) Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J Clin Invest 112: 725-735.
24. Guzik TJ, Sadowski J, Guzik B, Jopek A, Kapelak B, et al. (2006) Coronary artery superoxide production and Nox isoform expression in human coronary artery disease. Arterioscler Thromb Vasc Biol 26: 333-339.
25. Ellmark SH, Dusting GJ, Fui MW, Guzzo-Pernell N, Drummond GR (2005) The contribution of Nox 4 to NADPH oxidase activity in mouse vascular smooth muscle. Cardiovascular Research 65: 495-504.
26. Getz GA, Reardon CA (2006) Diet and murine atherosclerosis. Arterioscler Thromb Vasc Biol 26: 242-249.
27. Kamari Y, Werman-Venkert R, Shaish A, Werman A, Harari A, et al. (2007) Differential role and tissue specificity of interleukin-1α gene expression in atherogenesis and lipid metabolism. Atherosclerosis 195: 31-38.
28. Ray KK, Camp NJ, Benett CE, Francis SE, Crossman DC (2002) Genetic variation at the IL-1 locus is a determinant of changes in soluble endothelial factors in patients with acute coronary syndromes. Clinical Science 103: 303-310.
29. Bedard K, Krause K-H (2007) The NOX family of ROS-generating NADPH oxidases: Physiology and Pathophysiology. Physiol Rev 87: 245-313.
30. Kaur J, Dhaunsi GS, Turner RB (2004) Interleukin-1 and Nitric Oxide increase NADPH oxidase activity in human coronary artery smooth muscle cells. Medical Principles and Practice 13: 26-29.
31. Vergnes L, Phan J, Strauss M, Tafuri S, Reue K (2003) Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression. J Biol Chem 278: 42774-42784.
32. Wilde DW, Massey KD, Walker GK, Vollmer A, Grekin RJ (2000) High-fat diet elevates blood pressure and cerebrovascular muscle Ca(2+) current. Hypertension 35: 832-837.
33. Morris MC, Sacks F, Rosner B (1993) Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 88: 523-533.
34. Takeuchi H, Sakurai C, Noda R, Sekine S, Murano Y, et al. (2007 Antihypertensive effect and safety of dietary alpha-linolenic acid in subjects with high-normal blood pressure and mild hypertension. J Oleo Sci 56: 347-360.
35. Yang H, Kenny A (2007) The role of fish oil in hypertension. Conn Med 71: 533-538.
36. Massaro M, Habib A, Lubrano L, Del Turco S, Lazzerini G, et al. (2006) The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC epsilon inhibition. Proc Natl Acad Sci USA 103: 15184-15189.
37. Chen J, Kuhlencordt PJ, Astern J, Gyurko R, Huang PL (2001) Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice. Circulation 104: 2391-2394.
38. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, et al. (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356: 1517-1526.
39. Ikonomidis I, Lekakis JP, Nikolaou M, Paraslevaidis I, Andreadou I, et al. (2008) Inhibition of IL-1 by Anakinra improves vascular and LV function in patients with rheumatoid arthritis. Circulation 117: 2662-2669.
40. Abbate A, Salloum FN, Vecile E, Das A, Koke NH, et al. (2008) Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 117: 2670-2683.